TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00660816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally once daily on days 2-19.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed disodium
Description: Given IV over 10 minutes on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV over 10 minutes on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: IV over 60 minutes on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: IV over 60 minutes on day 1.
Study: NCT02098291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G17DT
Study: NCT00374452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ATHENA-CDS-HTN plus Guideline Link
Description: ATHENA display provides guideline-based recommendations to clinicians at the time of patient care.

Intervention type: OTHER
Group type: OTHER
Intervention: Guideline Link Only
Description: Primary care providers were sent, once, a link (URL) to the VA/DoD and JNC7 hypertension guidelines.
Study: NCT00159146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pindolol and venlafaxin
Description: pindolol 20 mg and venlafaxin 150 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pindolol and venlafaxin
Description: pindolol 20 mg and venlafaxin 150 mg
Study: NCT04139161

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Q-Factor Intervention
Description: The intervention period will consist of 12 training sessions across four consecutive weeks, with three training sessions held per week. If pain is not increased or reduced and Rating of Perceived Exertion is ≤12, the participant will progress to the next bout. If pain is increased from the pre-bout pain score, participants will repeat the bout, at the same workrate and Q-Factor settings. Following this fashion, participants will progress through three increasing Q-Factors for each given workrate; Q-Factor 1 (Q1, 192mm), Q2 (234mm), Q3 (276mm). After completing bouts of all three Q-Factors for a given workrate, workrate will be increased by 20 Watts and bouts at each Q-Factor will be repeated. For each training session, participants will complete bouts of cycling until 1) the maximum number of bouts (4 bouts) has been accomplished, 2) self-reported Rating of Perceived Exertion \>12, indicating a transition to moderate physical activity, or 3) self-reported pain \>5.
Study: NCT01334138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A 4-week diet, low in sodium.
Description: Study subjects receive personal advice to decrease sodium consumption and will change his diet for 28 days.~Follow up is performed by measuring blood pressure, a 24-hour urine sample collection, diaries and questionnaires.
Study: NCT02992054

Intervention type: OTHER
Intervention: stimulating activities
Study: NCT00119496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone
Description: oral tablet, 4mg bd for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: theophylline
Description: Oral theophylline, 200mg bd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: beclomethasone
Description: inhaled beclomethasone, 200mcg bd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled beclomethasone and oral theophylline
Description: inhaled beclomethasone (400mcg/day), oral theophylline (400mg/day)
Study: NCT02722265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150
Description: CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks
Study: NCT04040621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Description: Single intravenous infusion of ceftazidime-avibactam over 2 hours. Dosage will vary depending upon age, weight and renal function.
Study: NCT04566692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGSC 20%
Description: SC infusion pump.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGSC 20%
Description: SC infusion pump.
Study: NCT04839159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling before any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
Study: NCT01650662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: In the CsA group, at least 5 min before balloon inflation and stenting, patients will receive an intravenous bolus injection of 2.5 mg/kg of CsA. In the control group, patients will receive only recommended treatments. CsA will be dissolved in normal NaCl 0.9% solution (final concentration 25 mg/ml) and injected slowly (over 20-30 seconds) via a catheter positioned in an antecubital vein at least 5 min before PCI, to allow for distribution of the drug.
Study: NCT01183468

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aralast NP 45 mg dose
Description: - 45 mg/kg/week
Study: NCT01183468

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aralast NP 45 mg dose
Description: - 45 mg/kg/week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aralast NP 90 mg dose
Description: - 90 mg/kg/week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aralast NP 90 mg dose
Description: - 90 mg/kg/week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aralast NP 90 mg dose
Description: - 90 mg/kg/week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aralast NP 90 mg dose
Description: - 90 mg/kg/week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aralast NP 180 mg dose
Description: - 180 mg/kg/week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aralast NP 180 mg dose
Description: - 180 mg/kg/week
Study: NCT03740568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Progesterone
Description: Additional daily dosage of subcutaneous progesterone (Psc) 25 mg/day at night since D4 (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night) New Progesterone analysis on D5 before warming the embryo. Group 2a (Canceled Group, P on D5 \<10.64 ng/mL): cancel PGT-FET. Scheduling a new procedure under different P supplementation.~Group 2b (Restored Progesterone Group, P on D5 \>10.64 ng/mL): continue HRT as previously described (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night). Warming and transfer the same day (D5)~Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:~If P is \>10.64 ng /mL: the same P supplementation is continued. If P is \<10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night

Intervention type: DRUG
Group type: OTHER
Intervention: Normal Progesterone
Description: Same Progesterone supplementation (vaginal micronized P 200mg/200mg/200mg) Warming and transfer on D5~Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:~If P is \>10.64 ng /mL: the same P supplementation is continued. If P is \<10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night
Study: NCT02533336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abamectin and fenpyroximate
Study: NCT00169091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 12.5 mg on Day 1 to up to 300 mg on Day 12.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 2 mg on Day 1 to up to 12 mg on Day 12.
Study: NCT01496755

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single/multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG7667
Description: Single/multiple ascending doses
Study: NCT03095456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revefenacin
Description: Revefenacin administered via nebulization.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Spiriva Handihaler®
Description: Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Revefenacin
Description: Placebo administered as double blind, double dummy via nebulization.
Study: NCT01012323

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NewGam
Description: The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as minimum trough levels of serum immunoglobulin G (IgG) was above 5 g/L. If serum IgG trough levels dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
Study: NCT01063088

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine (split virion, inactivated, prepared in Vero Cell cultures)
Description: Single 0.5 mL intramuscular injection
Study: NCT01229449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen/acetaminophen
Description: One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet, single dose taken orally with 300 ml water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen/acetaminophen (higher dose)
Description: Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg, single dose taken orally with 300 ml water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nurofen Plus®
Description: Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®), single dose taken orally with 300 ml water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panadeine® Extra
Description: Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra), single dose taken orally with 300 ml water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets, single dose taken orally with 300 ml water
Study: NCT02619032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Intraoperative continuous infusion of remifenatanil. Remifentanil infusion was interrupted upon completion of surgical intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Intraoperative continuous infusion of remifenatanil. Remifentanil infusion was interrupted upon completion of surgical intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 50 μg iv bolus at the induction of anesthesia and before the start of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 50 μg iv bolus at the induction of anesthesia and before the start of surgery.
Study: NCT03203291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TPAD (Tethered Pelvic Assist Device)
Description: Each day of intervention will include a 1-hour treadmill based intervention to promote increased loading onto the affected limb. Visual feedback will be provided and faded over the course of the 5-day training. Immediately on completion of the treadmill intervention, participants will receive an additional 5-10 minutes of overground intervention reinforcing weight shifting onto the affected limb.
Study: NCT00737633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: Phentermine 15 mg/Topiramate controlled release (CR) 92 mg, oral capsule, once daily, 58 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: Phentermine 15 mg/Topiramate controlled release (CR) 92 mg, oral capsule, once daily, 58 weeks
Study: NCT03327558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apriso 0.375G ER CAP
Description: ER capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APRISO 375 mg extended-release capsules
Description: 375 mg extended-release capsules
Study: NCT00293020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEMA Fentanyl
Description: buccal soluble film; 200, 400, 600, 800, 1200 mcg fentanyl; up to 4 times daily
Study: NCT01336023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.
Study: NCT01057563

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug (paclitaxel)-eluting balloon (DEB)
Description: BMS implantation after lesion predilation with DEB

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bare-metal stent (BMS)
Description: BMS implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug (paclitaxel)-eluting balloon (DEB)
Description: BMS implantation followed by post-dilation with DEB
Study: NCT00095173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: IV infusions, IV, 10mg/kg body weight, every 4 weeks, 6 months (unless a disease flare discontinued the patient earlier).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusions, IV, N/A, every 4 weeks, 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Solution, intravenous, Approximately 10 mg/kg fixed dose, based on subject's body weight; 500 mg for subjects weighing \< 60kg; 750 mg for subjects weighing 60 to 100 kg; and 1 gram for subjects weighing \> 100 kg, monthly
Study: NCT01563172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride / silica and carbopol, 0.5g
Description: Dentifrice containing 1150 parts per million (ppm) fluoride as sodium fluoride / silica and 0.4% carbopol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride / silica and carbopol, 0.5g
Description: Dentifrice containing 1150 parts per million (ppm) fluoride as sodium fluoride / silica and 0.4% carbopol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride / silica and carbopol, 1.5g
Description: Dentifrice containing 1150 ppm fluoride as sodium fluoride / silica and 0.4% carbopol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride / silica and carbopol, 1.5g
Description: Dentifrice containing 1150 ppm fluoride as sodium fluoride / silica and 0.4% carbopol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride / silica and carbopol, 1.5g
Description: Dentifrice containing 250 ppm fluoride as sodium fluoride / silica and 0.4% carbopol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride free dentifrice
Description: A non fluoride dentifrice was given to participants of each arm at washout period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride free dentifrice
Description: A non fluoride dentifrice was given to participants of each arm at washout period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride free dentifrice
Description: A non fluoride dentifrice was given to participants of each arm at washout period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride free dentifrice
Description: A non fluoride dentifrice was given to participants of each arm at washout period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride free dentifrice
Description: A non fluoride dentifrice was given to participants of each arm at washout period
Study: NCT02540265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Study: NCT01626417

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Tibion Bionic Leg
Description: The device is a lightweight, wearable, portable, battery-powered, robotic leg orthosis that provides active assistance and resistance to lower limb movement according to the patient's intent to move.
Study: NCT00908466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus (rapamycin)
Description: Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus (rapamycin)
Description: Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
Study: NCT00930007

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling for later hormone measurements

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling for later hormone measurements
Study: NCT00472966

Intervention type: DRUG
Group type: OTHER
Intervention: Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels
Description: Apply cream once daily at night. Subjects will be asked to discontinue use of Fluocinolone acetonide/hydroquinone/tretinoin Cream 2 days prior to the peel and restart 2 days after the peel; Glycolic Acid Peels - In office treatment at weeks 2, 4, 6, 8 and 10
Study: NCT01531751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Cut-off Hemodialysis
Description: During dialysis the patients will undergo the first cycle of chemotherapy according to the current standard of care for subjects with advanced cardiac AL amyloidosis. Measurements of FLC and cardiac biomarkers will be done before and after each dialysis session. High cutoff HD will be continued during the first chemotherapy cycle. After the first cycle the end-of-treatment evaluation will take place.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy will be based on alchilators, proteasome inhibitors, steroids, IMiDs.
Study: NCT03950310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer laser catheter
Description: The excimer laser catheter is equipped with multiple optical fibers on the periphery of the guide wire lumen corresponding to 0.014 inch, which is used for the purpose of reperfusion of barrier site of coronary artery. The connector on the front side is connected with the CVX-300 laser generator, and the tip at the top contact directly with the lesion. The laser catheter consisting of multiple optical fibers transmits the energy in the ultraviolet region from the CVX300 laser generator to the blockage in the blood vessel. The ultraviolet energy is transmitted from the tip of laser catheter, transpires the fibrous, calcified and arteriosclerotic lesion by light, and enables reperfusion in the lesion. The laser catheter has appropriate hydrophilic coating and easily follows the inside of coronary artery.
Study: NCT04060966

Intervention type: BEHAVIORAL
Intervention: Cold-Pressor Task (CPT)
Description: The CPT involves participants submerging their dominant forearm in ice-water (0-4°C) for 3 minutes.

Intervention type: BEHAVIORAL
Intervention: Cold-Pressor Task (CPT)
Description: The CPT involves participants submerging their dominant forearm in ice-water (0-4°C) for 3 minutes.

Intervention type: BEHAVIORAL
Intervention: Control CPT
Description: The control CPT involves participants submerging their dominant forearm in warm water (\~30°C) for 3 minutes.

Intervention type: BEHAVIORAL
Intervention: Control CPT
Description: The control CPT involves participants submerging their dominant forearm in warm water (\~30°C) for 3 minutes.

Intervention type: DEVICE
Intervention: fMRI
Description: Participants in the neuroimaging cohort will complete up to two fMRI experimental sessions on different days, with at least a day between sessions, each lasting approximately 2 hours. Imaging data will be collected with a Prisma 3T head- only scanner equipped with a head coil from Nova Medical.

Intervention type: DEVICE
Intervention: fMRI
Description: Participants in the neuroimaging cohort will complete up to two fMRI experimental sessions on different days, with at least a day between sessions, each lasting approximately 2 hours. Imaging data will be collected with a Prisma 3T head- only scanner equipped with a head coil from Nova Medical.
Study: NCT02950376

Intervention type: OTHER
Intervention: DSM-5 +Virtual reality-based addiction assessment system
Description: The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the beginning of withdrawl、3 months later、 6 months later and 1 year later and record the information synchronously.

Intervention type: OTHER
Intervention: Virtual reality-based addiction assessment system
Description: The healthy controls will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the baseline and 1 month later and record the information synchronously.

Intervention type: OTHER
Intervention: DSM-5 +Virtual reality-based addiction assessment system
Description: The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.In this group which is designed to construct the norm of assessment system, the test will record the information synchronously and proceed after baseline assessment.